Does treatment schedule matter? Once daily versus divided doses of 5-ASAs

Digestive Diseases

Volumn 28, Issue 3, 2010, Pages 478-482

  Kane, Sunanda ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adherence; Aminosalicylate; Mesalamine; Ulcerative colitis

Indexed keywords

MESALAZINE;

CLINICAL TRIAL; CONFERENCE PAPER; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MESALAMINE;

EID: 77957887132     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320405     Document Type: Conference Paper

References (22)

1. Klotz U, Maier K, Fischer C, Heinkel K: Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 1980; 303: 1499-1502.
2. Bloom BS: Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988; 84: 20-24.
3. Eisen SA, Miller DK, Woodward RS, Spitzna-gel E, Przybeck TR: The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-1884.
4. Kane SV, Cohen RD, Aikens JE, Hanauer SB: Predictors of non-compliance with mesala-mine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96:2929-2932.
5. Cervený P, Bortlík M, Kubena A, Vlcek J, Lakatos PL, Lukás M: Nonadherence in inflammatory bowel disease: results of factor analysis. inflamm Bowel Dis 2007; 13: 1244-1249.
6. Hussain FN, Ajjan RA, Kapur K, Moustafa M, Riley SA: Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001; 15 : 53-62.
7. Rubin D, Gavzy S, Chapman C, Mikolajczyk A, Surma B: Lumenal pH and transit time in patients with quiescent ulcerative colitis resembles that of healthy controls. Am J Gas-troenterol 2009; 104(suppl 3):S460 (abstract).
8. Sandborn WJ, Hanauer SV, Buch A: Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther 2004; 19: 1089-1098.
9. Wray H, Joseph R, Palmen M, Pierce D: A pharmacokinetic and scintigraphic comparison of MMX mesalamine and delayed-re-lease mesalamine. Am J Gastroenterol 2008; 103(suppl 3):S433 (abstract).
10. Parakkal D, Ehrenpreis ED, Thorpe MP, Putt KS, Hannon B: A dynamic model of once-daily 5-aminosalicylic acid predicts clinical efficacy. World J Gastroenterol 2009; 15: 1799-1804.
11. Farup PG, Hinterleitner TA, Lukas M, He-buterne X, Rachmilewitz D, Campierir M, Meier R, Keller R, Rathbone B, Oddsson E: Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least effective as prolonged-release tablets four times daily in patients with ul-cerative colitis. Inflamm Bowel Dis 2001; 7: 237-242.
12. Raedler A, Behrens C, Bias P: Mesalazine (5-aminosaliculic acid) micropellets show similar efficacy and tolerability to mesala-zine tablets in patients with ulcerative colitis: results from a randomized-controlled trial. Aliment Pharmacol Ther 2004; 20: 1353-1363.
13. Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE: MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007; 26: 205-215.
14. Andus T, Kocjan A, Muser M, Simanenkov V, Baranovsky A, Mikhailova T, Zvyagint-seva T, Dorofeyev A, Lozynskyy Y, Lavy A, Mohrbacher R, Grienwalkd R: A novel high dose 1 g mesalamine suppository (Salofalk) is as efficacious as 500 mg t.i.d. suppositories in mild to moderate active ulcerative procti-tis: a multicenter, randomized trial. Gastro-enterology 2008; 134(4 suppl):A491 (abstract).
15. Kane SV, Huo D, Magnanti K: A pilot feasibility trial of once daily vs. conventional dosing of mesalamine for treatment of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1: 170-173.
16. Kane S, Holderman W, Jacques P, Miodek T: Once Daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Prefer Adherence 2008; 2:253-258.
17. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R: Randomised trial of once-or twice-daily MMX mesalamine for maintenance of remission in ulcerative colitis. Gut 2008; 57: 893-902.
18. Dignass A, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Borner N, Silvennoinen J, Tan G, Oudkerk Pool M, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veer-man H: Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 762-769.
19. Sandborn WJ, Korzenik J, Lashner B, Leigh-ton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S: Once-daily dosing of delayed release oral mesalamine (400 mg tablet) for maintenance of remission i n ulcerat ive col itis: The QD dosing investigation for efficacy in UC maintenance trial. Gastroenterolog y 2010; 138: 1286-1296.
20. Kripalani S, Yao X, Haynes RB: Interventions to enhance medication adherence in chronic medical conditions: a systematic rev iew. Arch Intern Med 2007; 16 7: 540-550.
21. Gray JR, Leung E, Scales J: Treatment of ul-cerative colitis from the patient's perspective: a survey of preferences and satisfaction with therapy. Aliment Pharmacol Ther 2009; 29:1114-1120.
22. Kane S, Sumner M, Solomon D, Jenkins M: Factors affecting persistence with mesala-mine therapy: results from a large pharmacy database. Am J Gastroenterol 2009; 104 (suppl 3):A1272 (abstract).